Position in GUTS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$133,789
+$56,616 QoQ
Shares Held
168,500
0.0% QoQ
Ownership
0.106%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#31
of 76 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GUTS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Cerity Partners LLC holds $424,897,823 across 139 Biotechnology names. GUTS ranks #104 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
255,874 | $127,100,291 | |
| 2 | CORT |
Corcept Therapeutics Inc
|
797,119 | $69,309,495 | |
| 3 | HALO |
Halozyme Therapeutics, Inc.
|
343,589 | $26,892,710 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
39,274 | $24,488,909 | |
| 5 | INCY |
Incyte Corp
|
205,071 | $23,246,847 | |
| 6 | EXEL |
Exelixis, Inc.
|
377,130 | $20,519,642 | |
| 7 | JAZZ |
Jazz Pharmaceuticals plc
|
53,534 | $12,900,087 | |
| 8 | RPRX |
Royalty Pharma plc
|
180,772 | $10,135,884 |
All Filings in GUTS
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $133,789 | 168,500 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $77,173 | 168,500 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $359,700 | 163,500 | Shares | Sole | 2026-02-11 | |
| 2025-09-30 | $21,569 | 13,566 | Shares | Sole | 2025-10-22 | |
| 2025-06-30 | $29,947 | 18,486 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $16,335 | 13,727 | Shares | Sole | 2025-04-30 | |
| 2024-12-31 | $22,660 | 11,000 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $27,830 | 11,000 | Shares | Sole | 2024-11-12 | |
| No filing history on record for this holder in this stock. | ||||||